Simple Summary A proportion of breast tumors bear the oncogenic transmembrane tyrosine
kinase protein HER2. Even though therapies that target HER2 have changed the prognosis …

Purpose Breast cancer brain metastasis (BCBM) represents a major clinical challenge. Can
MRI help in advancements in the management of BCBM? This review discusses MRI …

Biomarker analysis of invasive breast carcinoma is useful for prognosis, as surrogate for
molecular subtypes of breast cancer, and prediction of response to adjuvant and …

Simple Summary The receptor HER2 is overexpressed in some breast cancers. Tumours
with a high HER2 expression can be successfully treated with the antibodies trastuzumab …

Background: Although the conversion of clinically used breast cancer biomarkers such as
estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor …

Purpose In stage IV breast cancer, the efficacy of human epidermal growth factor receptor 2
(HER2) targeted therapies in cases with discordance in HER2 expression between primary …

Molecular subtype of breast cancer has a great clinical significance and used as one of the
major criteria for therapeutic strategy. Recently, for anticancer therapy, the trend for …

PURPOSE: Despite the availability of current standards of care treatments for triple negative
breast cancer (TNBC), many patients still die from this disease. Quadruple negative tumors …

Background Hormone receptor (HR) and human epidermal growth factor receptor (HER2)
discordance between primary and metastatic breast cancer lesions is common. However, its …

Background changes may occur in tumor phenotype and receptor status during the
progression of breast cancer. Discordance between primary and metastases has …